MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

Search

Celldex Therapeutics Inc

Gesloten

SectorGezondheidszorg

27.15 3.67

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

25.88

Max

27.77

Belangrijke statistieken

By Trading Economics

Inkomsten

-2.8M

-57M

Verkoop

35K

730K

Winstmarge

-7,753.425

Werknemers

186

EBITDA

-1.1M

-63M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+99.77% upside

Dividenden

By Dow Jones

Volgende Winsten

4 nov 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

304M

1.8B

Vorige openingsprijs

23.48

Vorige sluitingsprijs

27.15

Nieuwssentiment

By Acuity

21%

79%

46 / 371 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Weak Bullish Evidence

Celldex Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

8 okt 2025, 20:45 UTC

Winsten

Costco Wholesale Sales Climb in September, Early October

8 okt 2025, 20:12 UTC

Belangrijke Marktbewegers
Acquisities, Fusies, Overnames

TaskUs Shares Fall After Holders Reject Take-Private Deal

8 okt 2025, 16:39 UTC

Belangrijke Marktbewegers

Mining Shares Rise as Gold Prices Soar

8 okt 2025, 23:45 UTC

Marktinformatie

Nikkei May Rise on Weaker Yen -- Market Talk

8 okt 2025, 23:43 UTC

Marktinformatie

Gold Falls on Possible Profit-Taking -- Market Talk

8 okt 2025, 23:18 UTC

Acquisities, Fusies, Overnames

JD Logistics to Finance Acquisition Using Internal Funds

8 okt 2025, 23:17 UTC

Acquisities, Fusies, Overnames

JD Logistics to Buy On-Demand Delivery Services Business for US$270.0M

8 okt 2025, 23:16 UTC

Acquisities, Fusies, Overnames

JD Logistics to Buy JD.com's On-Demand Delivery Services Business Dajiang and Dasheng

8 okt 2025, 21:54 UTC

Marktinformatie
Winsten

James Hardie Could Beat Annual Earnings Goal -- Market Talk

8 okt 2025, 21:30 UTC

Marktinformatie

Boab Metals Bull Delivers Second Upgrade in a Month -- Market Talk

8 okt 2025, 21:26 UTC

Marktinformatie
Winsten

Transurban's 1Q Traffic Growth Beats Hopes -- Market Talk

8 okt 2025, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

8 okt 2025, 19:15 UTC

Marktinformatie

Geopolitical Risk Supports Gains in Oil Futures -- Market Talk

8 okt 2025, 19:01 UTC

Marktinformatie

U.S. Natural Gas Futures Pull Back Ahead of Storage Data -- Market Talk

8 okt 2025, 18:47 UTC

Marktinformatie

Coca-Cola North America Sales Buoy International Weakness -- Market Talk

8 okt 2025, 18:46 UTC

Acquisities, Fusies, Overnames

TaskUs: Neither Party Will Be Required to Pay Termination Fee as Result of Planned Mutual Decision to Terminate

8 okt 2025, 18:46 UTC

Acquisities, Fusies, Overnames

TaskUs Will Remain a Publicly Traded Co >TASK

8 okt 2025, 18:46 UTC

Acquisities, Fusies, Overnames

TaskUs Does Not Plan to Convene Another Special Meeting of Stockholders >TASK

8 okt 2025, 18:45 UTC

Acquisities, Fusies, Overnames

TaskUs Didn't Receive Votes Necessary to Approve Transaction Agreement With Affil of Blackstone >TASK

8 okt 2025, 18:07 UTC

Marktinformatie

Mexico's Inflation Seen Edging Up in September -- Market Talk

8 okt 2025, 16:20 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Energy & Utilities Roundup: Market Talk

8 okt 2025, 16:20 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

8 okt 2025, 16:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

8 okt 2025, 15:57 UTC

Marktinformatie

Oil Rises Despite U.S. Crude Stockpiles Build -- Market Talk

8 okt 2025, 15:56 UTC

Marktinformatie

Teck Resources' Chile Mine Issues Appear Transitory -- Market Talk

8 okt 2025, 15:53 UTC

Marktinformatie

Argentine Sovereign Debt Seen as Attractive -- Market Talk

8 okt 2025, 15:44 UTC

Acquisities, Fusies, Overnames

Staar Surgical: Broadwood's Proposal to Vote Down Merger Could Allow It to Take Control Without Paying Any Premium

8 okt 2025, 15:44 UTC

Acquisities, Fusies, Overnames

Staar Surgical Board and Management Disagree With Recommendation Issued by Glass Lewis >STAA

8 okt 2025, 15:43 UTC

Acquisities, Fusies, Overnames

STAAR Surgical Board Reiterates Unanimous Recommendation Holders Vote for Alcon Merger

8 okt 2025, 15:42 UTC

Acquisities, Fusies, Overnames

Oracle Is a Buy-the-Dip Opportunity, Analyst Says. How the Stock Could Rise 23%. -- Barrons.com

Peer Vergelijking

Prijswijziging

Celldex Therapeutics Inc Prognose

Koersdoel

By TipRanks

99.77% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 52.38 USD  99.77%

Hoogste 67 USD

Laagste 38 USD

Gebaseerd op 10 Wall Street-analisten die 12-maands prijsdoelen bieden voor Celldex Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

10 ratings

10

Buy

0

Hold

0

Sell

Technische score

By Trading Central

18.91 / 20.63Steun & Weerstand

Korte Termijn

Weak Bullish Evidence

Gemiddeld Termijn

Bullish Evidence

Lange Termijn

Bearish Evidence

Sentiment

By Acuity

46 / 371 Rangschikking in Gezondheidszorg

Nieuwssentiment

Zeer Sterk Bearish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Celldex Therapeutics Inc

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.
help-icon Live chat